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Abstract
Background: Patients with atrial fibrillation (AF) and chronic kidney disease repre-
sent a high-risk group for thromboembolism and bleeding.
Aims: To explore the relationship between kidney function changes and outcomes 
of stroke/systemic embolism (SE), major bleeding and all-cause death in anticoagu-
lated AF patients participating in the BOREALIS trial comparing efficacy and safety 
of once-weekly s.c. idrabiotaparinux to that of warfarin.
Methods: Changes in kidney function by estimated glomerular filtration rate (eGFR) 
were calculated using the Chronic Kidney Disease Epidemiology Collaboration equa-
tion in 2765 AF patients. Trial adjudicated outcomes were determined.
Results: After a mean follow-up of 394 days, in 94.4% of the included patients kidney 
function changed ranging from −30 mL/min to 30 mL/min. The incidence of stroke/
SE and major bleeding was similar between patients with deteriorated (reduction in 
eGFR from baseline over follow-up) and preserved kidney function change (increase 
or no change in eGFR from baseline over follow-up) [stroke/SE: incidence rate (IR): 
1.33%/year vs 1.80%/year; hazard ratio (HR) 0.74, 95% confidence interval (CI) 0.41-
1.32, P = .30; major bleeding: IR 1.63%/year vs 1.49%/year, HR 1.10, 95% CI 0.61-
1.97, P = .76]. On Cox regression analysis, patients with deteriorated kidney function 
were at higher risk for all-cause death, compared to patients with preserved kidney 
function (HR: 1.64, 95% CI: 1.02-2.63, P = .04).
Conclusion: In the BOREALIS trial, the risk of adjudicated stroke/SE, major bleedings, 
and all-cause death was not related to mild-moderate follow-up changes in kidney 
function (±30 mL/min). The risk of all-cause death was significantly increased in AF 
patients with abruptly deteriorating kidney function.
K E Y W O R D S
deteriorated CKD-EPI eGFR change, major bleeding, all-cause death, preserved CKD-EPI 
eGFR change, stroke/systemic embolism
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1  | INTRODUC TION
Atrial fibrillation (AF) and chronic kidney disease (CKD) often com-
plicate each other1 and there is evidence that CKD markedly in-
creases the risk of stroke (even with the use of oral anticoagulation),2 
as well as bleeding and mortality in AF patients.3,4 Uncertainty exists 
among specialists on the best use of anticoagulation in AF patients 
with concomitant CKD.5 As there are few studies on the relationship 
between deterioration of kidney function and the adjudicated out-
comes of anticoagulation in patients with AF.
We performed a secondary analysis of evaluation of Weekly 
Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to 
Prevent Stroke and Systemic Thromboembolic Events in Patients 
with Atrial Fibrillation (BOREALIS) trial6 comparing idrabiotaparinux 
with vitamin K antagonists for prevention of thromboembolism in 
patients with AF to address the unclear associations between the 
relative risk of stroke, major bleeding, and mortality with changes in 
kidney function in AF.
2  | MATERIAL S AND METHODS
The design and results of the BOREALIS trial have previously been 
described and details provided in Supplemental Methods.6 In brief, 
the BOREALIS trial was a multicenter randomized trial comparing 
idrabiotaparinux and dose-adjusted warfarin for the prevention of 
thromboembolism in patients with nonvalvular AF.6 The trial proto-
col was approved by the institutional review board and all patients 
have provided written informed consent. The trial was stopped 
early, and showed a comparable effect in stroke and SE prevention 
of once-weekly s.c. idrabiotaparinux to that of warfarin, but with in-
conclusive noninferiority because the upper 95% confidence limit of 
the primary efficacy outcome (stroke/SE,1.66) was above the pre-
specified margin for noninferiority (1.38).
To be included in the present analysis: (a) patients should have 
baseline creatinine measurements; and (b) last creatinine measured 
within 90 days before the end of the study treatment or after the 
end of the study treatment. Consequently, patients were divided 
into two groups according to their kidney function changes, from 
baseline to the end of the follow-up, calculated using chronic kidney 
disease epidemiology collaboration (CKD-EPI) equation. Changes in 
kidney function were categorized as “preserved” (ie, increase or no 
change in eGFR from baseline over follow-up) or “deteriorated” (re-
duction in eGFR from baseline over follow-up). The “deteriorated” 
group included all individuals who had any level of deterioration in 
kidney function. Those with kidney function deterioration ≥40 mL/
min were defined as abrupt deterioration.
2.1 | Estimation of kidney function
Three widely used formulae were used to estimate the kidney func-
tions in each patient, as follows:
1. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)7 = 
141 × min (Scr/κ, 1)α × max(Scr/κ,1)−1.209 × 0.993Age × 1.018 (if 
female) × 1.159 (if African American), where κ is 0.7 for women 
and 0.9 for men, α is −0.329 for women and −0.411 for men, min 
indicates the minimum of Scr/κ or 1, max indicates the maximum 
of Scr/κ or 1, and Scr indicates serum creatinine levels, expressed 
in milligrams per deciliters;
2. The modification of diet in renal disease (MDRD)8 GFR (mL/min/1
.73 m2) = 175 × (Scr)−1.154 × (Age)−0.203 × (0.742 if female) × (1.212 
if African American); and
3. The Cockcroft -Gault Equation9 = (140 − age) × (Weight in kilo-
grams) × (0.85 if female)/(72 × Creatinine in milligrams per deciliter).
2.2 | Study endpoints
In this analysis we included all study outcomes, collected from 
the baseline to the end of the study. The primary analysis of the 
BOREALIS trial reported only outcomes collected during the treat-
ment period.6 The primary efficacy outcome of this analysis was the 
composite of stroke and systemic embolism (SE). The principal safety 
outcome of the present analysis was major bleeding, the definition 
of which was based on the criteria published.6,10 All-cause death 
was also studied in this study.6,10 Suspected outcome events were 
adjudicated by an independent central adjudication committee who 
were blinded to treatment assignment.
2.3 | Statistical analysis
Baseline characteristics were reported as numbers (percentages of ac-
tual numbers) or mean ± standard deviation (SD). Continuous variables 
between two kidney function change groups were compared using 
independent t test. Categorical variable comparisons between kidney 
function changes were conducted using Chi-squared test or Fisher's 
exact test. Univariate Cox regression analysis was used to estimate the 
hazard ratio of the outcomes of kidney function changes in different 
settings of the whole cohort, cohort complicated with diabetes mellitus 
(DM), hypertension (HPT), and heart failure (HF). Event rates (number 
per 100 patient-years) were also reported. Multivariate Cox regression 
analysis adjusted for age, sex, history of hypertension, diabetes, con-
gestive heart failure and/or left ventricular impairment, prior stroke/
SE, concomitant aspirin use, concomitant clopidogrel or ticagrelor use, 
and separately adjusted for kidney function changes (calculated with 
CKD-EPI eGFR, MDRD eGFR and CRCL, separately) or for baseline 
kidney function (calculated with CKD-EPI eGFR). Restricted cubic 
spline lines were used to explore the relationship of continuous kidney 
function changes with the outcomes of stroke/SE, major bleeding, and 
all-cause death. Data were considered as missing data if information 
was unavailable. Kaplan-Meier curves of outcomes in relation to differ-
ent kidney function changes were assessed. Analyses were performed 
using SPSS (version 23.0) and STATA 13 (STATA Inc) softwares. Two-
tailed P value < .05 was considered as statistically significant.
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3  | RESULTS
After a follow-up of 394 [208-531] days, 2765 participating AF pa-
tients in the BOREALIS trial had both measured creatinine variables 
at baseline and the end of study treatment. Baseline characteristics 
were compared between the deteriorated and preserved kidney 
function change (calculated using CKD-EPI eGFR) groups in AF pa-
tients randomized to the two anticoagulant treatment arms (Table 1). 
Those with deteriorated kidney function change had a tendency to 
have a higher mean HAS-BLED score and lower kidney function, 
but other baseline characteristics were not significantly different. 









Age   .55
N 1580 1185  
Mean ± SD 69.36 ± 9.68 69.14 ± 9.77  
Sex, N (%)   .55
Female 596 (37.7) 461 (38.9)  
Male 984 (62.3) 724 (61.1)  
BMI   .67
N 1579 1180  
Mean ± SD 29.98 ± 6.20 29.88 ± 5.97  
AF type, N (%)   .3
Paroxysmal AF 446 (28.3) 304 (25.9)  
Persistent AF 289 (18.3) 234 (19.9)  
Permanent AF 843 (53.4) 638 (54.3)  
Previous HPT, N (%)   .65
Yes 1480 (93.7) 1104 (93.2)  
No 100 (6.3) 81 (6.8)  
LV dysfunction, N (%)   .64
Yes 899 (56.9) 686 (57.9)  
No 680 (43.1) 499 (42.1)  
DM, N (%)   .83
Yes 546 (34.6) 404 (34.1)  
No 1034 (65.4) 781 (65.9)  
CAD, N (%)   .79
Yes 574 (38.9) 421 (38.3)  
No 900 (61.1) 677 (61.7)  
Previous stroke, TIA 
or non-CNS systemic 
embolism, N (%)
  .24
Yes 501 (31.7) 350 (29.5)  




Yes 475 (30.1) 325 (27.4)  




VKA 793 (50.2) 591 (49.9)  
Idraparinux 787 (49.8) 594 (50.1)  
Hb   1.00
N 1564 1165  
Mean ± SD 140.54 ± 16.08 142.86 ± 16.05  
Creatinine   <.001
N 1580 1185  










CKD-EPI eGFR   <.001
N 1580 1185  
Mean ± SD 71.25 ± 18.01 61.59 ± 16.93  
≤30 10 (0.6) 13 (1.1)  
30-60 432 (27.4) 591 (49.9)  




0-1 1 (0.06) 3 (0.3)  
2 156 (9.9) 110 (9.3)  
3 362 (22.9) 271 (22.9)  
4 434 (27.5) 353 (29.8)  
5 327 (20.7) 255 (21.5)  
≥6 299 (18.9) 193 (16.3)  
HAS-BLED score, N (%)   .04
0 154 (9.8) 129 (10.9)  
1 504 (31.9) 427 (36.1)  
2 566 (35.8) 417 (35.2)  
3 274 (17.4) 164 (13.9)  
≥4 81 (5.1) 47 (4.0)  
Categorical variables were presented as number (%); Continuous 
variables were presented as mean ± standard deviation (SD).
CHA2DS2-VASc, congestive heart failure, 1 point; hypertension, 1 point; 
age ≥ 75 years, 2 points; diabetes mellitus,1 point; stroke, 2 points; vascular 
disease, 1 point; age from 65 to 74 years, 1 point; and female sex, 1 point. 
HAS-BLED, uncontrolled hypertension (>160 mmHg systolic), 1 point; 
abnormal renal function, 1 point; or abnormal liver function, 1 point; 
Prior history of stroke, 1 point; Prior major bleeding or predisposition to 
bleeding, 1 point; labile INR, 1 point; age > 65 years, 1 point; prior Alcohol 
or Drug Usage History (≥ 8 drinks/week), 1 point; Medication Usage 
Predisposing to Bleeding: (Antiplatelet agents, NSAIDs), 1 point.
AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery 
disease; CKD-EPI eGFR, Chronic Kidney Disease Epidemiology 
Collaboration estimate glomerular filtration rate; CNS, central nervous 
system; DM, diabetes mellitus; HPT, hypertension; LV, left ventricular; 
TIA, transient ischemic attack; VKA, vitamin-K antagonist.
TA B L E  1   (Continued)
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Abrupt kidney function reduction of ≥40 mL/min occurred in 29 pa-
tients, which was 1.8% of the deteriorated group.
3.1 | Kidney function changes
The distribution of kidney function changes, calculated using three 
calculation methods and then categorized by 10 unit increments is 
shown in Figure S1. Of note, 94.4% (calculated using CKD-EPI eGFR), 
92.7% (MDRD eGFR), and 91.6% (CRCL) of kidney function changes 
ranged from −30 to 30 mL/min, while 77.8% of kidney function 
changes (CKD-EPI eGFR), 73.6% (MDRD eGFR), and 73.8% (CRCL) 
ranged from −15 to 15 mL/min.
3.2 | All-cause deaths
All-cause deaths included 9 strokes, 1 non-CNS systemic embolism, 
4 myocardial infarctions, 5 intracerebral hemorrhages, 3 subdural 
hematomas, 3 gastro-intestinal bleedings, 28 other cardiovascular 
deaths, and 25 other causes (cancer or sepsis). Figure S2 lists the 
distribution of all-cause deaths according to CKD-EPI estimate glo-
merular filtration rate (eGFR) changes categorized by 10 mL/min 
increments. Stroke (other than haemorrhage stroke [HS])/SE mainly 
occurred in AF patients with CKD-eGFR changes from −20 to 30 mL/
min, while other cardiovascular deaths (excluding myocardial infarc-
tion [MI]) and other causes of death (mainly sepsis and cancer) mainly 
from −80 to −20 mL/min.
3.3 | Thromboembolic outcomes according to 
kidney function changes
The incidence of stroke/SE events was similar between deteriorated 
(incidence rate (IR) 1.33) and preserved kidney function change 
(IR 1.80) (hazard ratio (HR): 0.74, 95% confidence interval (CI) 
0.41 − 1.32, P = .30) (Figure S3). There were consistent effects with 
nonsignificant differences between deteriorated and preserved 
kidney function changes in different settings of DM, HPT, and HF. 
Adjusted Cox regression analysis found no effect taking kidney 
function changes as continuous variables, whether calculated using 
CKD-EPI, MDRD, or Cockcroft-Gault equations (Table 2). There was 
no statistically significant association between the baseline kidney 
function, calculated by CKD-EPI equation, and thromboembolic 
events (HR: 1.02, 95% CI: 1.00-1.04, P = .06), in the separate ad-
justed Cox analysis.
F I G U R E  1   Restricted cubic spline 
for (A) stroke and systemic embolism, 
R2 = 0.94; (B) major bleeding, R2= 0.22; 
(C) all-cause death, (with kidney function 
changes ranging from −80 to 40 mL/
min) R2 = 0.995 (D) all-cause death (with 
kidney function changes ranging from −40 
to 40 mL/min), R2 = 0.65 with analysis 
of estimated kidney function changes 
from baseline to the end of treatment 
categorized by 10 units with CKD-EPI
TA B L E  2   Multivariate Cox regression analysis
 
CKD-EPI eGFR change MDRD eGFR change CRCL change
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Stroke/SE 1.00 (0.97-1.03) .95 1.01 (0.99-1.03) .17 1.00 (0.98-1.03) .70
Major bleeding 0.99 (0.96-1.02) .49 0.99 (0.97-1.01) .50 1.00 (0.97-1.02) .85
All-cause Death 0.96 (0.94-0.98) <.001 0.98 (0.97-0.99) <.001 0.98 (0.96-0.99) .005
CKD-EPI eGFR, Chronic Kidney Disease Epidemiology Collaboration estimate glomerular filtration rate; CRCL, the Cockcroft-Gault equation; MDRD 
eGFR, The modification of diet in renal disease estimate glomerular filtration rate; SE, systemic embolism.
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F I G U R E  2   Kaplan-Meier analysis for risk of stroke and systemic embolism, major bleeding, and all-cause death. (A) stroke/systemic 
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3.4 | Bleeding outcomes according to kidney 
function changes
The incidence of major bleeding events was similar between pre-
served (IR 1.63%/year) and deteriorated (IR 1.49%/year) kidney func-
tion changes in the whole group (HR: 1.10, 95% CI: 0.61-1.97, P = .76).
Consistency in bleeding risk was also seen in subgroups including 
DM, HPT, and HF. There were no significant associations between 
the changes in kidney function, calculated using the three estimation 
methods, and the risk of major bleeding (Table 2). A separate Cox 
model, adjusted for the baseline kidney function, did not show an 
association with the risk of major bleeding (HR: 0.99, 95% CI: 0.97-
1.01, P = .26).
Patients with a deteriorated change in kidney function were at 
higher risk for all-cause death (HR: 1.64, 95% CI: 1.02-2.63, P = .04), 
particularly in those complicated with hypertension (HR: 1.79, 95% 
CI: 1.07-2.98, P = .03) and heart failure (HR: 1.91, 95% CI: 1.03-3.56, 
P = .04). The annualized incidence of all-cause death in those with a 
deteriorated kidney function change was 3.19% per year compared 
to those with preserved kidney function change, being 1.94% per 
year (Figure S3).
Cox regression analysis showed negative independent associ-
ations between kidney function changes, assessed by all three es-
timation methods, and all-cause death (Table 2). Baseline kidney 
function, calculated by CKD-EPI eGFR formula, did not show inde-
pendent association with all-cause death (HR: 1.00, 95% CI: 0.98-
1.01, P = .82). As demonstrated in Figure 1, the incidence rate of 
all-cause death decreased with improved kidney function during 
the study treatment period (P < .001). If we restricted the analysis 
to those patients with mild-moderate changes in kidney function, 
that is, after excluding those with abrupt changes in kidney function 
(from −80 to −40), no significant difference was found between kid-
ney function changes ranging from −40 to 40 mL/min and all-cause 
death (P = .20). In 1041 patients, where kidney function deteriorated 
to CKD (eGFR < 60 mL/min) level by the end of follow-up period, the 
risk of all-cause death was increased (HR: 1.65, 95% CI: 1.06-2.57, 
P = .03) with no significant effect on the risk of major bleeding (HR: 
1.65, 95% CI: 0.93-2.95, P = .09) and stroke/SE (HR: 0.75, 95% CI: 
0.40-1.40, P = .36).
Kaplan-Meier analysis shows that patients with preserved kid-
ney function changes had a similar risk of stroke/ SE, (log-rank: 
P = .30), major bleeding, (log-rank: P = .76), but lower risk of all-cause 
death (log-rank: P = .04) compared to those with a deteriorated kid-
ney function change (Figure 2).
4  | DISCUSSION
In the BOREALIS trial population, the risk of all-cause mortality 
was significantly higher in anticoagulated AF patients whose kid-
ney function decreased abruptly over the study treatment period. 
Stroke/SE, major bleedings, and all-cause death were not related to 
mild-moderate changes in kidney function (±30 mL/min).
There remains a dilemma balancing stroke/SE and major bleed-
ing when oral anticoagulation is used in patients with concurrent 
AF and CKD.11 Patients with AF are also inclined to develop kid-
ney dysfunction.12,13 However, no significant difference in the risk 
of stroke/SE and major bleeding was seen in the present study 
between deteriorated and preserved kidney function during the 
anticoagulation treatment period, with similar kidney function 
change between VKA and idrabiotaparinux. One reason was per-
haps the narrow range of kidney function changes from baseline to 
the end of study treatment, as more than 70% of included patients 
had kidney function changes (calculated using three formulae) 
within 15 mL/min (from −15 to 15 mL/min) and more than 90% 
within 30 mL/min (from −30 to 30 mL/min). Previous meta-anal-
yses2,3 showed no significant increase in risk of major bleeding 
and stroke/SE if kidney function deteriorated within 30% of the 
baseline kidney function,14,15 the conclusion of which was further 
confirmed by our study because of similar kidney function change 
scope.
In previous studies of AF patients using warfarin for anticoag-
ulation, kidney dysfunction was a risk factor for death.16 However, 
no significant differences between baseline kidney function and 
mortality were found in the study of Marcos et al.17 In our anal-
ysis, we assessed kidney function using three different formulae 
and found that an abrupt deteriorated change in kidney function 
over time was associated with an increased risk of all-cause mor-
tality. If study was restricted to those patients with mild-moder-
ate changes in kidney function (ranging from −40 to +40 mL/min), 
no significant association was found between kidney function 
changes and all-cause mortality. Also, other cardiovascular deaths 
(excluding myocardial infarction [MI]) and other causes of death 
(mainly sepsis and cancer) constituted most of “all-cause deaths” 
in AF patients with CKD-eGFR changes from −80 to −40 mL/min 
(Figure S2).
Subgroup analyses found similar risks of stroke/SE and major 
bleeding in patients with deteriorated and preserved kidney func-
tion with DM, HPT, and HF. Preserved kidney function was associ-
ated with a lower risk of all-cause death compared with deteriorated 
kidney function in patient subgroups with HF and hypertension, but 
not in those with DM.
4.1 | Limitations
The strength of this analysis is the adjudicated clinical outcomes from 
the posthoc analysis of this trial cohort, but there are several limi-
tations to be mentioned for this study. First, these posthoc analyses 
from the BOREALIS trial should be interpreted as hypothesis generat-
ing only, especially given the limited statistical power for some smaller 
subgroups. Second, most of the changes in kidney function ranged 
from −30 to 30 mL/min, and the majority of AF patients enrolled had 
relatively stable kidney function. Therefore, the results should be cau-
tiously extrapolated to those patients with sharp changes in kidney 
(dys)function. Third, the underlying pathogenic mechanism(s) were 
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not explored. Finally, we cannot account for the multiple drug therapy 
changes (and dose alterations) over the follow-up period.
5  | CONCLUSIONS
In this trial cohort of anticoagulated AF patients, the risk of all-
cause death was significantly increased in AF patients showing 
abruptly deteriorating kidney function. There were no significant 
effects on the risk of stroke/SE, major bleeding, and all-cause 
death were seen when kidney function changed from −30 to 
30 mL/min.
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